PDGFs and PDGFRs in canine osteosarcoma: New targets for innovative therapeutic strategies in comparative oncology

Veterinary Journal

Volumn 195, Issue 1, 2013, Pages 41-47

  Maniscalco, Lorella ^a   Iussich, Selina ^a   Morello, Emanuela ^a   Martano, Marina ^a   Biolatti, Bartolomeo ^a   Riondato, Fulvio ^a   Salda, Leonardo Della ^b   Romanucci, Mariarita ^b   Malatesta, Daniela ^b   Bongiovanni, Laura ^b   Tirrito, Federica ^a   Gattino, Francesca ^a   Buracco, Paolo ^a   De Maria, Raffaella ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TERAMO   (Italy)

Author keywords

Canine osteosarcoma; Comparative oncology; PDGF; PDGF receptor; Targeted therapy

Indexed keywords

6,7 DIMETHOXY 2 PHENYLQUINOXALINE; CISPLATIN; DOXORUBICIN; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; TUMOR MARKER;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; COMPARATIVE STUDY; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; FEMALE; IN VITRO STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHUMAN; ONCOLOGY; OSTEOSARCOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE; ANIMAL; DOG DISEASE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; TUMOR CELL LINE; VETERINARY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOG DISEASES; DOGS; GENE EXPRESSION REGULATION, NEOPLASTIC; OSTEOSARCOMA; PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84871426233     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2012.05.003     Document Type: Article

References (51)

1. Alvarez R.H., Kantarjian H.M., Cortes J.E. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clinic Proceedings 2006, 81:1241-1257.
2. Berg J., Weinstein M.J., Springfield D.S., Rand W.M. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. Journal of the American Veterinary Medical Association 1995, 206:1555-1560.
3. Chen C.L., Loy A., Cen L., Chan C., Hsieh F.C., Cheng G., Wu B., Qualman S.J., Kunisada K., Yamauchi-Takihara K., Lin J. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer 2007, 28:111.
4. Chun R., Garrett L.D., Henry C., Wall M., Smith A., Azene N.M. Toxicity and efficacy of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma. Journal of the American Animal Hospital Association 2005, 41:382-387.
5. Dacasto M., Nebbia C., Bollo E. Triphenyltin acetate (TPTA)-induced cytotoxicity to mouse thymocytes. Pharmacological Research 1994, 29:179-186.
6. De Maria R., Miretti S., Iussich S., Olivero M., Morello E., Christensen J.G., Biolatti B., Levine R.A., Buracco P., Di Renzo M.F. MET oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma. Journal of Pathology 2009, 218:399-408.
7. Dernell W.S., Ehrhart N.P., Straw R.C., Vail D.M. Tumors of the skeletal system. Withrow & MacEwen's Small Animal Clinical Oncology 2007, 540-582. Ed. Saunders Elsevier, St. Louis, MO, USA. Fourth Ed.
8. Donnem T., Al-Saad S., Al-Shibli K., Andersen S., Busund L.T., Bremnes R.M. Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells. Journal of Thoracic Oncology 2008, 3:963-970.
9. Farese J.P., Kirpensteijn J., Kik M., Bacon N.J., Waltman S.S., Seguin B., Kent M., Liptak J., Straw R., Chang M.N., Jiang Y., Withrow S.J. Biologic behavior and clinical outcome of 25 dogs with canine appendicular chondrosarcoma treated by amputation: A veterinary society of surgical oncology retrospective study. Veterinary Surgery 2009, 38:914-919.
10. Ferrari S.S., Bertoni F., Zanella L.E., Bacchini P., Alberghini M., Versari M., Bacci G. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer 2004, 100:1936-1942.
11. Fjällskog M.L., Lejonklou M.H., Oberg K.E., Eriksson B.K., Janson E.T. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clinical Cancer Research 2003, 9:1469-1473.
12. Flint A.F., U'Ren L., Legare M.E., Withrow S.J., Dernell W., Hanneman W.H. Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors. Veterinary Pathology 2004, 41:291-296.
13. Fossey S.L., Liao A.T., McCleese J.K., Bear M.D., Lin J., Li P.K., Kisseberth W.C., London C.A. Characterization of STAT3 activation and expression in canine and human osteosarcoma. BMC Cancer 2009, 10:81.
14. Freeman S.S., Allen S.W., Ganti R., Wu J., Ma J., Su X., Neale G., Dome J.S., Daw N.C., Khoury J.D. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer 2008, 113:1453-1461.
15. Gorlik R., Huvos A.G., Heller G., Aledo A., Beardsley G.P., Healey J.H., Meyers P.A. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. Journal of Clinical Oncology 1999, 17:2781-2788.
16. Higgins R.J., Dickinson P.J., LeCouteur R.A., Bollen A.W., Wang H., Wang H., Corely L.J., Moore L.M., Zang W., Fuller G.N. Spontaneous canine gliomas: Overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping. Journal of Neuro-oncology 2010, 98:49-55.
17. Horner A., Bord S., Kemp P., Grainger D., Compston J.E. Distribution of platelet-derived growth factor (PDGF) A chain mRNA, protein, and PDGF - Alpha receptor in rapidly forming human bone. Bone 1996, 19:353-362.
18. Johnson A.S., Couto C.G., Weghorst C.M. Mutation of the p53 tumor suppressor gene in spontaneously occurring osteosarcomas of the dog. Carcinogenesis 1998, 19:213-217.
19. Kaseta M.K., Khaldi L., Gomatos I.P., Tzagarakis G.P., Alevizos L., Leandros E., Papagelopoulos P.J., Soucacos P.N. Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma. Journal of Surgery Oncology 2008, 97:259-266.
20. Kempf-Bielack B., Bielack S.S., Jurgens H., Branscheid D., Berdel W.E., Exner G.U., Gobel U., Helmke K., Jundt G., Kabisch H., Kevric M., Klingebiel T., Kotz R., Maas R., Schwarz R., Semik M., Treuner J., Zoubek A., Winkler K. Osteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). Journal of Clinical Oncology 2005, 23:559-568.
21. Khanna C., Lindblad-Toh K., Vail D., London C., Bergman P., Barber L., Breen M., Kitchell B., McNeil E., Modiano J.F., Niemi S., Comstock K.E., Ostrander E., Westmoreland S., Withrow S. The dog as a cancer model. Nature Biotechnology 2006, 24:1065-1066.
22. Korpi J.T., Hagström J., Lehtonen N., Parkkinen J., Sorsa T., Salo T., Laitinen M. Expression of matrix metalloproteinases-2, -8, -13, -26, and tissue inhibitors of metalloproteinase-1 in human osteosarcoma. Surgical Oncology 2011, 20:18-22.
23. Kubo T., Piperdi S., Rosenblum J., Antonescu C.R., Chen W., Kim H.S., Huvos A.G., Sowers R., Meyers P.A., Healey J.H., Gorlick R. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 2008, 112:2119-2129.
24. Lachowicz J.L., Post G.S., Brodsky E. A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats. Journal of Veterinary Internal Medicine 2005, 19:860-864.
25. Lana S.E., Ogilvie G.K., Hansen R.A., Powers B.E., Dernell W.S., Withrow S.J. Identification of matrix metalloproteinases in canine neoplastic tissue. American Journal of Veterinary Research 2000, 61:111-114.
26. Levine R.A., Forest T., Smith C. Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors. Veterinary Pathology 2002, 39:372-378.
27. Liu K.W., Hu B., Cheng S.Y. Platelet-derived growth factor receptor alpha in glioma: A bad seed. Chinese Journal of Cancer 2011, 30:590-602.
28. London C.A. Tyrosine kinase inhibitors in veterinary medicine. Topics in Companion Animal Medicine 2009, 24:106-112.
29. London C.A., Malpas P.B., Wood-Follis S.L., Boucher J.F., Rusk A.W., Rosenberg M.P., Henry C.J., Mitchener K.L., Klein M.K., Hintermeister J.G., Bergman P.J., Couto G.C., Mauldin G.N., Michels G.M. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clinical Cancer Research 2009, 15:3856-3865.
30. Loukopoulos P., Robinson W.F. Clinicopathological relevance of tumour grading in canine osteosarcoma. Journal of Comparative Pathology 2007, 136:65-73.
31. Loukopoulos P., O'Brien T., Ghoddusi M., Mungall B.A., Robinson W.F. Characterisation of three novel canine osteosarcoma cell lines producing high levels of matrix metalloproteinases. Research in Veterinary Science 2004, 77:131-141.
32. Ma P.C., Maulik G., Christensen J., Salgia R. C-Met: Structure, functions and potential for therapeutic inhibition. Cancer Metastasis Reviews 2003, 22:309-325.
33. MacEwen E.G., Kutzke J., Carew J., Pastor J., Schmidt J.A., Tsan R., Thamm D.H., Radinsky R. C-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clinical and Experimental Metastasis 2003, 20:421-430.
34. MacEwen E.G., Pastor J., Kutzke J., Tsan R., Kurzman I.D., Thamm D.H., Wilson M., Radinsky R. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. Journal of Cellular Biochemistry 2004, 92:77-91.
35. Morello E., Martano M., Buracco P. Biology, diagnosis and treatment of canine appendicular osteosarcoma: Similarities and differences with human osteosarcoma. The Veterinary Journal 2011, 189:268-277.
36. Nicholson K.M., Anderson N.G. The protein kinase B/Akt signalling pathway in human malignancy. Cellular Signalling 2002, 14:381-395.
37. östman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine & Growth Factor Reviews 2004, 15:275-286.
38. Ottaviani G., Jaffe N. The epidemiology of osteosarcoma. Cancer Treatment and Research 2009, 152:3-13.
39. Pontén F., Ren Z., Nistér M., Westermark B., Pontén J. Epithelial-stromal interactions in basal cell cancer: The PDGF system. Journal of Investigative Dermatology 1994, 102:304-309.
40. Seger R., Krebs E.G. The MAPK signaling cascade. FASEB Journal 1995, 9:726-735.
41. Slayter M.V., Boosinger T.R., Pool R.R., Dammrich K., Misdorp W., Larsen S. Histological Classification of Bone and Joint Tumors of Domestic Animals 1994, vol. 1. Armed Forces Institute of Pathology, Washington DC, USA. Second Ed.
42. Straw R.C., Withrow S.J., Richter S.L., Powers B.E., Klein M.K., Postorino N.C., LaRue S.M., Ogilvie G.K., Vail D.M., Morrison W.B., McGee M. Amputation and cisplatin for treatment of canine osteosarcoma. Journal of Veterinary Internal Medicine 1991, 5:205-210.
43. Sulzbacher I., Träxler M., Mosberger I., Lang S., Chott A. Platelet-derived growth factor-AA and -alpha receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma. Modern Pathology 2000, 13:632-637.
44. Sulzbacher I., Birner P., Trieb K., Träxler M., Lang S., Chott A. Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Modern Pathology 2003, 16:66-71.
45. Sulzbacher I., Birner P., Dominkus M., Pichlhofer B., Mazal P.R. Expression of platelet-derived growth factor-alpha receptor in human osteosarcoma is not a predictor of outcome. Pathology 2010, 42:664-668.
46. Sundberg C., Ljungström M., Lindmark G., Gerdin B., Rubin K. Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. American Journal of Pathology 1993, 143:1377-1388.
47. Tokunaga E., Oki E., Egashira A., Sadanaga N., Morita M., Kakeji Y., Maehara Y. Deregulation of the Akt pathway in human cancer. Current Cancer Drug Targets 2008, 8:27-36.
48. Uren A., Merchantm M.S., Sun C.J., Vitolo M.I., Sun Y., Tsokos M., Illei P.B., Ladanyi M., Passaniti A., Mackall C., Toretsky J.A. Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells. Oncogene 2003, 22:2334-2342.
49. Vail D.M., MacEwen E.G. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Investigation 2000, 18:781-792.
50. Withrow S.J., Powers B.E., Straw R.C., Wilkins R.M. Comparative aspects of osteosarcoma. Dog versus man. Clinical Orthopaedics and Related Research 1991, 991:159-168.
51. Wu, X., Cai, Z.D., Lou, L.M., Zhu, Y.B., 2011. Expressions of p53, c-MYC, BCL-2 and apoptotic index in human osteosarcoma and their correlations with prognosis of patients. Cancer Epidemiology September 2 (Epub ahead of print).